Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …

Aging is a physiological process mediated by numerous biological and genetic pathways,
which are directly linked to lifespan and are a driving force for all age-related diseases …

Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the
mechanisms underlying the plasma glucose level-lowering effects of metformin (1, 1 …

Although death is inevitable, individuals have long sought to alter the course of the ageing
process. Indeed, ageing has proved to be modifiable; by intervening in biological systems …

Guideline Summary Chronic limb-threatening ischemia (CLTI) is associated with mortality,
amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are …

Thyroid dysfunction and diabetes mellitus are closely linked. Several studies have
documented the increased prevalence of thyroid disorders in patients with diabetes mellitus …

Background: Several pharmacologic options for type 2 diabetes are available. Purpose: To
compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes. Data …

Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global
cartographic picture of diabetes by the International Diabetes Federation (http://www …

DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate
insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 …

The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
ADA's current clinical practice recommendations and is intended to provide the components …